Branchalwood Medical Practice

People with Type 2 Diabetes Mellitus using GLP-1 oral and injectable medications may face supply shortages

There is a worldwide shortage of a group of drugs used in the management of Type 2 Diabetes Mellitus.

This includes:

  • Ozempic® 0.5mg & 1mg solution for injection
  • Trulicity® 0.75 mg, 1.5 mg, 3 mg and 4.5 mg solution for injection
  • Rybelsus® 3mg, 7mg, 14mg tablets
  • Victoza® (Liraglutide) 6mg/ml solution for injection
  • Byetta® 5 & 10 mcg/0.02ml solution for injection
  • Bydureon® 2mg/0.85ml prolonged-release suspension for injection

Due to increased global use, manufacturers are currently unable to produce enough of these medicines to meet demand. We have been advised that supply is not expected to return to normal until at least the middle of 2024. This will be a very difficult time for people with diabetes who have problems accessing their medication and for their clinicians who are unable to provide the treatment they feel is necessary.


NHS Lanarkshire’s Adult Diabetes Service is working closely with colleagues in pharmacy and GP practices to ensure that people who are affected are provided with appropriate support and advice.


If you are currently using one of these medications and have recently obtained a prescription, please do not worry. If you are due to renew your prescription in the next two to three weeks, please speak to your community pharmacy about their expectation regarding available supplies. If your pharmacy is unable to get your medication for you, it may be necessary to contact the practice to discuss alternative treatment. To do so, you can submit your request via AskmyGP or via phone on 01698 372 888.


Please visit NHS Lanarkshire’s website for the most up-to-date information on this.